CYTOGENETIC CHANGES IN CAGES OF SYSTEM OF BLOOD AT PATIENTS WITH ULCERATIVE COLITIS AGAINST TREATMENT BY SULFASALAZINE
https://doi.org/10.51523/2708-6011.2010-7-4-8
Abstract
Cytogenetic changes in cages of peripheral blood at 62 patients with ulcerative colitis (UC) against standard treatment by sulfasalazine with use of a method of light microscopy are studied. It is established, that sulfasalazine in standard doses at patients with UC with fast type acetylation promoted accumulation neutrophils with presence of high level of segmentation, neutrophils in final phases of development and did not interrupt progressing of the basic pathogenetic link of this disease - аpoptosis. At slow acetylator with UC standard doses of sulfasalazine allowed to reduce formation neutrophils with presence of low level of segmentation, neutrophils on initial phases of development and promoted interruption pathological аpoptosis, disease causing development, i. e. UC.
About the Authors
E. I. Mikhailova
Gomel State Medical University
Belarus
Belarus
T. V. Satyrova
Gomel State Medical University
Belarus
Belarus
References
1. The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment. A double-blind trial on patients asymptomatic for one year / P. Riis [et al.] // Scand. J. Gastroenterol. - 1973. - Vol. 8. - P. 71-74.
2. Punchard, N. A. Mechanism of action of 5-aminosalicylic acid / N. A Punchard, S. M. Greenfield, R. P. H. Thompson // Mediators of Inflammation. - 1992. - Vol. 1. - P. 151-165.
3. Azad Khan, A. K. The effect of the acetylator phenotype on the metabolism of sulphasalazine in man / A. K. Azad Khan, M. Nurazzaman, S. С. Truelove // Journal of Medical genetics. - 1983. - Vol. 20. - P. 30-36.
4. Schroder, H. The polymorphic acetylation of sulphapyridine in man / H. Schroder, D.A.P. Evans // J. Med. Genet. - 1972. - № 9. - P. 168-171.
5. Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease / M. E. Sharp [et al] // Eur. J. Clin. Pharmacol. - 1981. - Vol. 21. - P. 243-250.
6. Schroder, H. Acetylator phenotype and adverse effects of sulfasalazine in healthy subjects / H. Schroder, D.A.P. Evans // Gut. - 1972. - № 13. - P. 278-284.
7. Side-effect profile of 200 patients with inflammatory arthritis treated with sulfasalazine / M. Farr [et al.] // Drugs. - 1986. - Vol. 32. - P. 49-52.
8. Red cell abnormalities associated with sulfasalazine maintenance therapy for ulcerative colitis / R. E. Pounder [et al.] // Gut. - 1975. - Vol. 16. - P. 181-185.
9. Witt, R. L. Induction of kinetochore positive and negative micronuclei in mouse bone marrow cells by salicylazosulfapyridine and sulfapyridine / K. L. Witt, R. Gudi, J. P. Bishop // Mutat Res. - 1992. - Vol. 283, № 1. - P. 53-57.
10. In vitro induction of chromosome damage by sulphasalazine in human lymphocytes / J. M. Mackay [et al.] // Mutation Research / Genet. Toxicol. - 1989. - Vol. 222, № 1. - P. 27-36.
11. Основанный на доказательствах Европейский консенсус по диагностике и лечению язвенного колита / Нац. Группа по воспалительным заболеваниям кишечника Респ. Беларусь; редкол.: Ю. Х. Мараховский [и др.]. - Минск, 2008. - 216 с.
12. Mechanistic studies on genotoxicity and carcinogenicity of salicylazosulfapyridine an anti-inflammatory medicine / M. J. Iatropoulos [et al.] // Exp. Toxicol. Pathol. - 1997. - Vol. 49, № 1/2. - P. 15-28.
13. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship brtween metabolites and the response to treatment in inpatients / K. M. Das [et al.] // Gut. - 1973. - Vol. 14. - P. 631-636.
Review
For citations:
Mikhailova E.I., Satyrova T.V. CYTOGENETIC CHANGES IN CAGES OF SYSTEM OF BLOOD AT PATIENTS WITH ULCERATIVE COLITIS AGAINST TREATMENT BY SULFASALAZINE. Health and Ecology Issues. 2010;(4):43-48. (In Russ.) https://doi.org/10.51523/2708-6011.2010-7-4-8
Views: 276
Email this article 